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In brief
Analogous to placing puzzle pieces that
look similar, mapping sequences to
regions of the genome that look similar is
challenging. Wagner et al. describe a new
Genome in a Bottle Consortium resource
for benchmarking accuracy of human
genome sequencing in more challenging
regions of the genome.
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SUMMARY

Genome in a Bottle benchmarks are widely used to help validate clinical sequencing pipelines and develop
variant calling and sequencing methods. Here we use accurate linked and long reads to expand benchmarks
in 7 samples to include difficult-to-map regions and segmental duplications that are challenging for short
reads. These benchmarks add more than 300,000 SNVs and 50,000 insertions or deletions (indels) and include
16% more exonic variants, many in challenging, clinically relevant genes not covered previously, such as
PMS2. For HG002, we include 92% of the autosomal GRCh38 assembly while excluding regions problematic
for benchmarking small variants, such as copy number variants, that should not have been in the previous
version, which included 85% of GRCh38. It identifies eight times more false negatives in a short read variant
call set relative to our previous benchmark. We demonstrate that this benchmark reliably identifies false positives and false negatives across technologies, enabling ongoing methods development.
INTRODUCTION
Advances in genome sequencing technologies have continually
transformed biological research and clinical diagnostics, and
benchmarks have been critical to ensure the quality of the
sequencing results. The Genome in a Bottle Consortium (GIAB)

developed extensive data1 and widely used benchmark sets to
assess the accuracy of variant calls resulting from human
genome sequencing.2–4 To use these benchmarks, the Global
Alliance for Genomics and Health (GA4GH) Benchmarking
Team developed tools and best practices for benchmarking.5
These benchmarks and benchmarking tools helped enable the
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Table 1. Summary comparison of v.3.3.2 and v.4.2.1 HG002 benchmark sets
Reference Build

Benchmark set

Reference included

SNVs

Indels

Base pairs in seg dups
and low mappability

GRCh37

v.3.3.2

87.8%

3,048,869

464,463

57,277,670

GRCh37

v.4.2.1

94.1%

3,353,881

522,388

133,848,288

GRCh38

v.3.3.2

85.4%

3,030,495

475,332

65,714,199

GRCh38

v.4.2.1

92.2%

3,367,208

525,545

145,585,710

Shown are metrics calculated for chromosomes 1–22 in GRCh37 and GRCh38, with variant counts and inclusion of segmental duplications (seg dups)
and regions that appear similar to short reads (i.e., ‘‘low mappability’’ regions where 100-bp read pairs have 2 or less mismatches and a 1 or less indel
difference from another region of the genome).

development and optimization of technologies and bioinformatics approaches, including linked reads,6 highly accurate long
reads,7 deep-learning-based variant callers,8,9 graph-based
variant callers,10 and de novo assembly.11,12 As these new technologies and methods accessed increasingly challenging
regions of the genome, studies highlighted many known medically relevant genes that were excluded from these previous
benchmarks.7,13–15 These studies demonstrated the need for
improved benchmarks covering segmental duplications, the
major histocompatibility complex (MHC), and other challenging
regions. A separate synthetic diploid benchmark was generated
from assemblies of error-prone long reads for two haploid hydatidiform mole cell lines, but this had limitations in terms of cell line
availability and small insertion or deletion (indel) errors because
of the high error rate of the long reads.16
Many of the difficult regions of the genome lie in segmental
duplications and other repetitive elements. Linked reads have
been shown to have the potential to expand the GIAB benchmark
by 68.9 Mbp to some of these segmental duplications.6 A circular
consensus sequencing (CCS) method was recently developed
that enables highly accurate 10- to 20-kb-long reads.7 This technology identified a few thousand likely errors in the GIAB benchmark, mostly in long interspersed nuclear elements (LINEs). It also
had more than 400,000 variants in regions mappable with long
reads but outside the benchmark, and it covered many difficultto-map, medically relevant genes that are challenging to call using
short reads or lower-accuracy long reads. GIAB recently used
these data to produce a local diploid assembly-based benchmark
for the highly polymorphic MHC region.
Here we use linked reads and long reads to expand GIAB’s
benchmark to include challenging genomic regions for the GIAB
pilot genome NA12878 and the GIAB Ashkenazi and Han Chinese
trios from the Personal Genome Project, which are more broadly
consented for genome sequencing and commercial redistribution
of reference samples.17 We more carefully exclude segmental
duplications that are copy number variant (CNV) in the GIAB samples18 or missing copies in GRCh37 or GRCh3819,20 because these
currently cannot be reliably benchmarked for small variants. We
also refined the methods used to produce the diploid assemblybased MHC benchmark21 to include most of the MHC region in
each member of the trio. We show that our benchmark reliably
identifies false positives (FPs) and false negatives (FNs) across a
variety of short-, linked-, and long-read technologies. The benchmark has already been used to develop and demonstrate new
variant callers in the precisionFDA Truth Challenge V2.22
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RESULTS
The new benchmark covers more of the reference,
including many segmental duplications
GIAB previously developed an integration approach to combine
results from different sequencing technologies and analysis
methods, using expert-driven heuristics and features of the
mapped sequencing reads to determine at which genomic positions each method should be trusted. This integration approach
excludes regions where all methods may have systematic errors
or locations where methods produce different variants or
genotypes and have no evidence of bias or error. The previous
version (v.3.3.2) primarily used a variety of short-read
sequencing technologies and excluded most segmental
duplications.4 Our new HG002 v.4.2.1 benchmark adds long
and linked reads to cover 6% more of the autosomal assembled
bases for GRCh37 and GRCh38 than v.3.3.2 (Table 1). The
median coverage by linked- and long-read datasets for each
genome is shown in Table S1. We also replace the mappingbased benchmark with assembly-based benchmark variants
and regions in the MHC.21 v.4.2.1 adds more than 300,000 single
nucleotide variants (SNVs) and 50,000 indels compared with
v.3.3.2. In STAR Methods, we detail the creation of the v.4.2.1
benchmark, including using the new long- and linked-read
sequencing data in the GIAB small variant integration pipeline
and identifying regions that are difficult to benchmark, including
potential large duplications in HG002 relative to the reference as
well as problematic regions of GRCh37 or GRCh38.
Many of the benchmark regions expanded by v.4.2.1 are in
segmental duplications and other regions with low mappability
for short reads (Figures 1 and S1; Table 1). GRCh38 has
270,860,615 bases in segmental duplications and low-mappability regions (regions difficult to map with paired 100-bp reads)
on chromosomes 1–22, including modeled centromeres. v.4.2.1
covers 145,585,710 (53.7%) of those bases, whereas v.3.3.2
covers 65,714,199 bases (24.3%). However, v.4.2.1 still
excludes some difficult regions and structural variants (SVs); of
the bases in GRCh38 chromosomes 1–22 not covered by
v.4.2.1, segmental duplication and low-mappability regions account for 56.4% of those bases.
To identify the types of genomic regions where v.4.2.1 gains
and loses benchmark variants relative to v.3.3.2, we compared
the variant calls in v.4.2.1 with v.3.3.2 and used the v.2.0
GA4GH/GIAB stratification files.22 Figure 1B highlights stratified
genomic regions with the largest SNV gains and losses in v.4.2.1
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Figure 1. The new benchmark set includes more of the reference genome and more variants
(A) Percentage of the genomic region that is included by HG002 v.3.3.2 and v.4.2.1 of all non-gap, autosomal GRCh38 bases; the MHC; low-mappability regions
and segmental duplications; and 159 difficult-to-map, medically relevant genes described previously.
(B) The number of unique SNVs by genomic context. Circle size indicates the total number of SNVs in the union of v.3.3.2 and v.4.2.1. Circles above the diagonal
indicate a net gain of SNVs in the newer benchmark, and circles below the diagonal indicate a net loss of SNVs in the newer benchmark.

versus v.3.3.2 (the full information is available in Table S2). As expected, the inclusion of linked and long reads leads to more
variants in v.4.2.1 than v.3.3.2 in segmental duplications, selfchains, the MHC region, as well as other regions that are difficult
to map with short reads. The gain in v.4.2.1 relative to v.3.3.2 is
lower in tandem repeats and homopolymers because v.4.2.1 excludes any tandem repeats and homopolymers not completely
included by the benchmark regions. Partially included tandem
repeats and homopolymers in v.3.3.2 caused some errors in
benchmarking results when v.3.3.2 missed variants in the repeat
but outside the benchmark regions, so partially included repeats
were completely excluded in v.4.2.1.
In addition to including more difficult regions, v.4.2.1 also corrects or excludes errors in v.3.3.2. In previous work, variants
called from PacBio HiFi were benchmarked against v.3.3.2,
and 60 SNV and indel putative false positives were manually
curated, which identified 20 likely errors in v.3.3.2.7 All 20 errors
were corrected in the v.4.2.1 benchmark or removed from the
v.4.2.1 benchmark regions. Twelve of these errors in v.3.3.2
result from short reads that were only from one haplotype
because reads from the other haplotype were not mapped
because of a cluster of variants in a LINE; two of these v.3.3.2 errors are excluded in v.4.2.1, and 10 variants are correctly called
in v.4.2.1 (Table S3). To verify the v.4.2.1 variants incorrectly
called by v.3.3.2 in LINEs, we confirmed all 274 tested variants
in 4 LINEs across the 7 samples using long-range PCR followed
by Sanger sequencing, as described in STAR Methods and
Table S4.
The new benchmark includes additional challenging
genes
To focus analysis on potential genes of interest, we analyzed inclusion of genes previously identified to have at least one exon

that is difficult to map with short reads, which we call ‘‘difficultto-map, medically relevant genes.’’13 v.4.2.1 covers 88% of
the 10,009,480 bp in difficult-to-map, medically relevant genes
on primary assembly chromosomes 1–22 in GRCh38, much
larger than the 54% covered by v.3.3.2 (Table S5).
3,913,104 bp of the difficult-to-map, medically relevant genes
lie in segmental duplication or low-mappability regions. The
v.4.2.1 benchmark includes 2,928,012 bp (74.8%) of those
segmental duplications and low-mappability regions, whereas
the v.3.3.2 benchmark includes 208,882 bp (5.3%). Future
work will be needed to include 49 of the 159 genes on chromosomes 1–22 that still have less than 90% of the gene body
included (Figure 2A), such as a recently published assemblybased approach.20 For example, 5 genes that have potential
duplications in HG002 were previously partially included in
v.3.3.2 but are excluded in v.4.2.1 because new methods will
be needed to resolve and represent benchmark variants in duplicated regions (Figure 2B). The medically relevant gene KIR2DL1
was partially included in v.3.3.2 but is now completely excluded
because the copy number variable KIR region is removed from
the v.4.2.1 benchmark regions. v.4.2.1 also does a better job
excluding regions that are duplicated in the benchmark sample
relative to the reference, specifically because it excludes regions
with higher-than-normal PacBio HiFi and/or Oxford Nanopore
(ONT) coverage (Figure 3). We detail the inclusion of each
difficult-to-map, medically relevant gene in Table S6.
PMS2 is an example of a medically important gene involved
with DNA mismatch repair that is included more by v.4.2.1
(85.6%) than by v.3.3.2 (25.9%) for HG002 (Figure 4). Variant
calling in PMS2 is complicated by the presence of the pseudogene PMS2CL, which contains identical sequences in many of
the exons of PMS2 and is within a segmental duplication.23
Using long-range PCR followed by Sanger sequencing, we
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Figure 2. v.4.2.1 includes many more difficult-to-map, medically relevant genes
(A) Cumulative distribution of the percentage of each gene included in HG002 v.4.2.1 benchmark regions for 159 autosomal difficult-to-map, medically relevant
genes. Dashed lines indicate that the number of genes included more than 90% increased from 19 in v.3.3.2 to 110 in v.4.2.1.
(B) Pairwise comparison of difficult-to-map, medically relevant gene inclusion in the benchmark set. Genes falling on the dashed line are similarly included by both
benchmark sets, whereas genes above (red fill) or below (blue fill) the dashed line are included more by the v.4.2.1 or v.3.3.2 benchmark set, respectively. The
genes included more by v.4.2.1 tend to be in segmental duplications, and the smaller number of genes included more by v.3.3.2 are mostly genes duplicated in
HG002 relative to GRCh38 and should be excluded.

confirmed 1,516 v.4.2.1 benchmark variants in PMS2 and 20
other difficult-to-map, medically relevant genes across the 7
samples, and only 4 in PKD1 and 1 in FCGR2B were discordant
with Sanger. The 5 discordant variants appeared to be clearly
supported by short and long reads, and the reason for the discordant Sanger result was unclear. Detailed Sanger sequencing
results for each gene and sample are shown in Table S4.
Comparison with platinum genomes identifies fewer
potential errors in v.4.2.1
Platinum Genomes identified SNVs that were Mendelian inconsistent because of being called heterozygous in all 17 individuals
in a pedigree with short read sequencing (‘‘category 1’’ errors).24
Some of these heterozygous calls result from regions duplicated
in all individuals in the pedigree relative to GRCh37. Therefore,
category 1 SNVs matching SNVs in our benchmarks may identify
questionable regions that should have been excluded from the
benchmark regions. 326 category 1 SNVs matched HG002
v.4.2.1 SNVs, a decrease relative to the 719 category 1 SNVs
matching HG002 v.3.3.2 SNVs. This suggests that v.4.2.1 better
excludes duplications in HG002 relative to the reference even as

4 Cell Genomics 2, 100128, May 11, 2022

it expands into more challenging segmental duplication regions.
However, the remaining 326 matching SNVs may be areas for
future improvement in v.4.2.1. Manual curation of 10 random
SNVs in HG002 v.4.2.1 that matched category 1 variants showed
that 5 were in possible duplications that potentially should be
excluded, and 5 were in segmental duplication regions that
may have been short read mapping errors or more complex variation in segmental duplications (Table S7). Particularly, clusters
of v.4.2.1 variants matching category 1 variants appeared to
be likely errors in v.4.2.1. We also compared the v.4.2.1
HG001 benchmark with the 2017 hybrid short-read benchmark
from Platinum Genomes, which uses an orthogonal approach
based on including variants with genotypes phased as expected
in the 17-member pedigree. The concordance between v.4.2.1
and Platinum Genomes in the intersection of both benchmark regions was 99.96% on GRCh37 and GRCh38. Curation identified
most differences as likely short-read mapping biases in Platinum
Genomes because 454 of 654 GIAB-specific and 1,857 of 2,203
Platinum Genomes-specific variants on GRCh37 fell in lowmappability regions and segmental duplications. In addition,
relative to the short-read-based Platinum Genomes benchmark
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Figure 3. Genes in the KIR locus are excluded in v.4.2.1 because of duplication in HG002
Medically relevant genes in the KIR locus, such as KIR2DL1, were partially included in v.3.3.2 with many erroneous variants but are correctly excluded by v.4.2.1
because of a likely duplication and other structural variation. Thick blue bars indicate regions included by each benchmark, and orange and light blue lines
indicate positions of homozygous and heterozygous benchmark variants, respectively. A duplication of part of this region, which is common in the population, is
supported by higher-than-normal coverage and high variant density across all technologies as well as alignment of multiple contigs from the maternal trio-based
HG002 Hifiasm assembly (Hifiasm-maternal). The region is very challenging to characterize and assemble accurately because of high variability and copy number
polymorphisms in the population as well as segmental duplications (shaded regions).

regions, the v.4.2.1 benchmark regions have substantially fewer
small gaps that can cause problems when benchmarking4 so
that the NG50 size of benchmark regions in v.4.2.1 is more
than two times greater than Platinum Genomes (Figure S2).
High Mendelian consistency in trios
To further evaluate the accuracy of the benchmark, we evaluated
the Mendelian consistency of our v.4.2.1 benchmark sets for the
son, father, and mother in two trios from GIAB of Ashkenazi
ancestry (HG002, HG003, and HG004) and Han Chinese
ancestry (HG005, HG006, and HG007). In the intersection of
the benchmark regions for the Ashkenazi trio, this evaluation
identified 2,502 variants that had a genotype pattern inconsistent
with Mendelian inheritance of the 4,968,730 variants in at least
one member of the trio (0.05%), slightly below the rate for
v.3.3.2 (2,494 of 4,383,371 or 0.06%) on GRCh38. The Mendelian inconsistency rates for the GIAB Han Chinese trio were lower
than for the Ashkenazi trio, 821 of 4,601,643 (0.02%) for v.4.2.1
and 790 of 4,138,328 (0.02%) for v.3.3.2. We separately
analyzed Mendelian inconsistent variants that were potential
cell line or germline de novo mutations (that is, the son was heterozygous and both parents were homozygous reference) and
those that had any other Mendelian inconsistent pattern (which
are unlikely to have a biological origin). Of 2,502 violations in
HG002, 1,177 SNVs and 284 indels were potential de novo mutations, 67 more SNVs and 71 more indels than in v.3.3.2.4
HG005 had only 162 potential de novo SNVs and indels.
Following manual inspection of 10 random de novo SNVs in
HG002, 10 of 10 appeared to be true de novo. After manual inspection of 10 random de novo indels, 10 of 10 appeared to be
true de novo indels in homopolymers or tandem repeats. The violations that were not heterozygous in the son and homozygous
reference in both parents fell in a few categories: (1) clusters of
variants in segmental duplications where a variant was missed
or incorrectly genotyped in one individual, (2) complex variants
in homopolymers and tandem repeats that were incorrectly
called or genotyped in one individual, and (3) some overlapping

complex variants in the MHC that were correctly called in the trio
but the different representations were not reconciled by our
method (even though we used a method that is robust to most
differences in representation).4,25 We exclude all Mendelian inconsistencies that are not heterozygous in the son and homozygous reference in both parents from the v.4.2.1 benchmark
regions of each member of the trio because most are unlikely
to have a biological origin. Conservative paternal|maternal
phasing for HG002 on GRCh38 was performed for the MHC using local diploid assembly and outside the MHC using phasing
that was consistent between trio analysis and integrated
Strand-seq and PacBio HiFi phasing (1,812,845 of 2,449,937
heterozygous benchmark variants).
Regions excluded from the benchmark
A critical part of forming a reliable v.4.2.1 benchmark was to
identify regions that should be excluded from the benchmark.
In Table 2 and Figure S3, we detail each region type that is
excluded, the size of the regions, and reasons for exclusion.
We describe how each region is defined in STAR Methods.
These excluded regions fall into several categories: (1) the
modeled centromere and heterochromatin in GRCh38 because
these are highly repetitive regions and generally differ in structure and copy number between any individual and the reference;
(2) the VDJ, which encodes immune system components
and undergoes somatic recombination in B cells; (3) in
GRCh37, regions that are expanded or collapsed relative to
GRCh38; (4) segmental duplications with more than 5 copies
longer than 10 kb and identity greater than 99%, where errors
are likely in mapping and variant calling (e.g., because of structural or copy number variation resulting in calling paralogous
sequence variants);26,27 (5) potential large duplications that are
in HG002 relative to GRCh37 or GRCh38; (6) putative insertions,
deletions, and inversions greater than 49 bp in size and flanking
sequence; and (7) tandem repeats larger than 10,000 bp where
variants can be difficult to detect accurately given the length of
PacBio HiFi reads. As an example of the importance of carefully
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Figure 4. The difficult-to-map, medically relevant gene PMS2 is better included in v.4.2.1
The medically relevant gene PMS2 is 85.6% included in the v.4.2.1 benchmark regions, whereas it is 25.9% included in v.3.3.2 because segmental duplications
(shaded regions) were largely excluded in previous benchmark versions. Thick blue bars indicate regions included by each benchmark, and orange and light blue
lines indicate positions of homozygous and heterozygous benchmark variants, respectively. This region is challenging for assembly-based approaches, and an
extra contig from the maternal trio-based HG002 Hifiasm assembly (Hifiasm-maternal) aligned to the left half of the gene because of misalignment or misassembly.

excluding questionable regions, when comparing variants from
ultralong reads with v.3.3.2, 74% of the putative FPs in HG002
on GRCh38 fell outside the v.4.2.1 benchmark regions
(Tables S8 and S9). Many of these were in centromere regions
that have very few benchmark variants but were erroneously
included in the v.3.3.2 short-read-based benchmark; e.g., in
chromosome 20 (chr20). Our new benchmark correctly excludes
these regions from the benchmark because they cannot be
confidently mapped with short, linked, or long reads used to
form the benchmark. Table S10 describes refinements to these
excluded regions between the initial draft release and the
v.4.2.1 benchmark.
Evaluation and manual curation demonstrates reliability
of the benchmark
GIAB has established a community evaluation process for draft
benchmarks before the official release, following the reliable
identification of errors (RIDE) principle for benchmarks.3 The
RIDE principle is designed to ensure that, when comparing
state-of-the-art query call sets with the benchmark, at least
50% of the putative false positives and false negatives are errors
in the query call set and not errors in the benchmark. GIAB recruited volunteer experts in particular variant calling methods
to follow the GA4GH Benchmarking Team’s best practices5 to
compare a variety of query variant call sets with the draft benchmarks. We performed the community evaluation on v.4.1 for
HG002. Based on this evaluation, we made small improvements
to generate v.4.2.1 for HG002 as well as for the other 6 samples
(Table S10). v.4.2.1 is the version described in the rest of this
manuscript for all samples.
Query call sets for the final evaluation performed on v.4.1 represented a broad range of sequencing technologies and bioinformatics methods (Table S11; STAR Methods). Each call set
developer curated a random selection of FPs and FNs to ensure
that the benchmark reliably identifies errors in the query call set.
Overall, we found that the benchmark was correct and the query
call set was not correct in the majority of FP and FN SNVs and
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indels (Figure 5, with all curations in Table S12). Overall, 433 of
452 (96%) curated FP and FN SNVs and indels inside v.3.3.2
benchmark regions and 422 of 463 (91%) outside v.3.3.2
benchmark regions were determined to be correct in the v.4.1
benchmark. Some technologies/variant callers, particularly
deep-learning-based variant callers using HiFi data, had more
sites where it was unclear whether the benchmark was correct
or the query call set was correct. These sites tended to be
near regions with complex structural variation or places that appeared to be inside potential large duplications in HG002 but
were not identified in our CNV approaches. In general, most sites
that were not clearly correct in the benchmark and wrong in the
query were in regions where the answer was unclear with current
technologies (Figure 5B). For example, the v.4.1 benchmark
correctly excludes much of the questionable region in Figure S4
but still includes some small regions where there may be a duplication and the variant calls in the benchmark and the query are
questionable. Future work will be aimed at developing a new
benchmark in the small fraction of questionable regions, but
these evaluations demonstrate that the new benchmark reliably
identifies FPs and FNs across a large variety of variant call
sets, including those based on short, linked, and long reads,
as well as mapping-based, graph-based, and assembly-based
variant callers.
New benchmark regions are enriched for false
negatives
We demonstrate the benchmarking utility of v.4.2.1 by
comparing an example query call set to the new and old benchmark sets for HG002. For a standard short-read-based call set (Ill
GATK-BWA in Figure 5), the number of SNVs missed (even when
including filtered variants) was 8.5 times higher when benchmarking against v.4.2.1 than against v.3.3.2 (16,615 versus
1,960). The difference is largely due to false negative SNVs in regions of low mappability and segmental duplications with 15,220
in v.4.2.1 versus 1,381 in v.3.3.2. When counting conservatively
filtered SNVs as false negatives, v.4.2.1 detected 71,165 more
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Table 2. Base pairs overlapping different types of difficult regions that are excluded from all input call sets for HG002
Bases excluded
in GRCh37

Bases excluded
in GRCh38

Modeled centromere and
heterochromatin

N/A

58,270,517

highly repetitive regions with modeled
reference sequences that are difficult to
characterize and structurally variable

VDJ

3,482,644

3,348,717

a region that undergoes somatic
recombination

Regions that are collapsed
and expanded from GRCh37/38
primary assembly alignments

17,702,248

N/A

regions of GRCh37 with identified issues, so
benchmark small variant calls are generally
not as reliable

Segmental duplications with >5
copies, >99% identity, and longer
than 10 kb

1,026,737

2,094,143

highly similar duplications with many copies
in the reference make it difficult to identify
which segmental duplication is the correct
location for small variants, and variants
could be from structural variants or
additional copies of the sequence in
HG002 not in the reference

Potential increased copy
number in HG002

21,595,779

28,679,205

difficult to identify in which copy of region
the small variants are, could be at a location
in GRCh37/38 or at the extra copy
of the region in HG002; no standards
for representation or benchmarking in
these regions

Inversions

843,244

893,369

would need to have a joint small and
structural variant benchmark for reliable
benchmarking

v.0.6 GIAB tier 1 plus tier 2
SV benchmark expanded by 150%

39,371,460

39,560,707

would need to have a joint small and
structural variant benchmark for
reliable benchmarking

Tandem repeats >10 kb

1,736,692

4,486,559

these repeats are similar to or longer than
the read lengths for all input datasets,
making variant calls less reliable

Difficult region description

Explanation of exclusion

The table shows progressive subtraction of other difficult regions, so each row has all rows above it subtracted before calculating overlapping base
pairs. In non-gap regions on chromosomes 1–22, there are 158,845,257 bp in GRCh37 and 202,943,679 bp in GRCh38 that are excluded by v.4.2.1
(i.e., outside the v.4.2.1 benchmark regions).

errors (183,568 in v.4.2.1 versus 112,403 in v.3.3.2), similar to the
increases seen with the noisy long-read-based Syndip benchmark relative to v.3.3.2.16 Also similar to Syndip, the number of
false positive SNVs was higher for v.4.2.1 (25,328) than v.3.3.2
(13,788) before conservative filtering. However, the number
of false positive SNVs was actually lower for v.4.2.1 (1,539)
than v.3.3.2 (2,370) after conservative filtering, likely because
of removal of potential structural and copy number variants
in v.4.2.1. Relative to Syndip, v.4.2.1 for HG002 covers about 1%
fewer autosomal bases in GRCh38 but 16% more bases in
regions of low mappability and segmental duplications.
Comparison of the results from the first and second precisionFDA challenges (based on v.3.2 and v.4.2, respectively)
demonstrated similar changes in performance when expanding
the benchmark; the combined false positive and false
negative rates for SNVs increased by 2- to 10-fold when the
five top performers of the first challenge were benchmarked
against v.4.2.22 The more challenging variants and regions
included in v.4.2.1 enable further optimization and development
of variant callers in segmental duplications and low-mappability
regions.

DISCUSSION
We present the first diploid small variant benchmark that uses
short, linked, and long reads to confidently characterize a broad
spectrum of genomic contexts, including non-repetitive regions
as well as repetitive regions, such as many segmental duplications, difficult-to-map regions, homopolymers, and tandem repeats. We demonstrated that the benchmark reliably identifies
false positives and false negatives in more challenging regions
across many short-, linked-, and long-read technologies and
variant callers based on traditional methods, deep learning,8,9
graph-based references,10 and diploid assembly.12 The benchmark was used in the precisionFDA Truth Challenge V2 held in
2020. This challenge focused on difficult regions not covered
well by the v.3.2 benchmark used in the first Truth Challenge in
2016, and SNV error rates of the winners of the first Truth Challenge increase by as much as 10-fold when evaluated against
the v.4.2 benchmark compared with the v.3.2 benchmark.22
We designed this benchmark to cover as much of the human
genome as possible with current technologies as long as the
benchmark genome sequence is structurally similar to the
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Figure 5. Summary of manual curations from the evaluation of the v.4.1 benchmark, demonstrating that it reliably identifies FPs and FNs in 13
call sets from different technologies and variant callers
(A) For each call set, we curated 20 FPs and 20 FNs, and this shows the proportion of curated FP and FN variants where the benchmark set was correct, and the
query call set was incorrect. The dashed black line indicates the desired majority threshold, 50%. Half of the curated variants were from GRCh37, and half were
from GRCh38.
(B) Breakdown of the total number of variants by category determined during manual curation, where the benchmark curation bar indicates whether the
benchmark variant and genotype were determined to be correct and the query curations color indicates whether the query variant and genotype were determined
to be correct.
(A and B) Excluded in (B) are variants from (A), where the benchmark was deemed correct and the query incorrect and shows that most of these sites were difficult
to curate.
(C) Benchmark-unsure variants by call set. ONT, Oxford Nanopore; PB, PacBio HiFi; Ill, Illumina PCR-free; 10X, 10X Genomics.

GRCh37 or GRCh38 reference. As a linear reference-based
benchmark, it has advantages over global de novo assemblybased approaches by using reference information to resolve
highly homozygous regions and some of the segmental duplications and other repeats where our samples are similar to the
reference assembly. This reference-based approach enables
users to take advantage of the suite of benchmarking tools
developed by the GA4GH Benchmarking Team, including
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sophisticated comparison of complex variants, standardized
performance metrics, and stratification by variant type and
genome context.5 However, our approach necessitates carefully
excluding regions where our reference samples differ structurally
from GRCh37 or GRCh38 because of errors in the reference,
gaps in the reference, CNVs, or SVs. Developing benchmarks
in these regions will require development of methods to characterize these regions with confidence (e.g., using diploid
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assembly), standards for representing variants in these regions,
and benchmarking methodology and tools. For example, for
variants inside segmental duplications for which the individual
has more copies than the reference, methods are actively being
developed to assemble these regions,26 but no standards exist
for representing on which copy the variants fall or how to
compare with a benchmark.
We expect that future benchmarks will increasingly use highly
contiguous diploid assembly to access the full range of genomic
variation. Our current benchmark is helping to enable this transition by identifying opportunities to improve assemblies in the
genome regions that are structurally similar to GRCh37 and
GRCh38.

B
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Limitations of the study
It is critical to understand the limitations of any benchmark.
Because our current benchmark excludes regions that
structurally differ from GRCh37 or GRCh38, it will not identify deficiencies in mapping-based approaches because of their reliance
on these references or highlight advantages of assembly-based
approaches that do not rely on these references. Although we
have tried to exclude all regions where our samples differ structurally from the reference, some regions with gains in copy number
and other large structural variants remain, particularly in
segmental duplications where these are more challenging to identify. Similarly, we may not exclude all inversions, particularly those
mediated by segmental duplications. In addition, the benchmark
still excludes many indels between 15 and 50 bp in size. We
also do not characterize mosaic variants, so methods detecting
somatic or mosaic variants may identify true variants missing
from the benchmark. Although we have significantly increased
our inclusion of difficult-to-map, medically relevant genes, more
work remains. Many of these genes are excluded because of putative SVs or copy number gains, and future work will be needed to
understand whether these are true SVs or copy number gains, and
if so, how to fully characterize these regions. The genomes characterized in this work come from individuals of European, Ashkenazi Jewish, and Han Chinese ancestry, and future benchmarks
are needed to understand any potential differences in variant
benchmarking for other ancestries.
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STAR+METHODS
KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

Extensive data for GIAB samples are available
at the NCBI SRA in the GIAB BioProject

GIAB

NCBI BioProject: PRJNA200694

Complete Genomics paired end 26 3 26 bp,
1003 coverage, processed by Complete
Genomics pipeline

GIAB

NCBI SRA: SRX852932 to SRX852936

Illumina PCR-free paired end 150 3 150 bp,
3003 coverage for HG001-HG004 and
1003 coverage for HG006 and HG007

GIAB

NCBI SRA: SRX1049768 to SRX1049855,
SRX847862 to SRX848317

Illumina PCR-free paired end 250 3 250 bp,
3003 coverage for HG005 and 40-503
coverage for HG001-HG004

GIAB

NCBI SRA: SRX1388368 to SRX1388459,
SRX1726841 to SRX1726859,
SRX1726861 to SRX1726869

Illumina 6 kb mate-pair, 133 coverage
for HG002-HG007

GIAB

NCBI SRA: SRX1388732 to SRX1388743

PacBio HiFi/CCS Sequel II

Wenger et al 2020

NCBI SRA: SRX7083054 to SRX7083059

Mother from CEPH Utah Pedigree (HG001)

NIST Office of Reference
Materials; Coriell/NIGMS

NIST RM8398; GM12878;
RRID: CVCL_7526

Son of Ashkenazi Jewish ancestry (HG002)

NIST Office of Reference
Materials; Coriell/NIGMS; PGP

NIST RM8391/RM8392;
GM24385; RRID: CVCL_1C78

Father of Ashkenazi Jewish ancestry (HG003)

NIST Office of Reference
Materials; Coriell/NIGMS; PGP

NIST RM8392; GM24149;
RRID: CVCL_1C54

Mother of Ashkenazi Jewish ancestry (HG004)

NIST Office of Reference
Materials; Coriell/NIGMS; PGP

NIST RM8392; GM24143;
RRID: CVCL_1C48

Son of Han Chinese ancestry (HG005)

NIST Office of Reference
Materials; Coriell/NIGMS; PGP

NIST RM8393; GM24631;
RRID: CVCL_1C97

Father of Han Chinese ancestry (HG006)

Coriell/NIGMS; PGP

GM24694; RRID: CVCL_1C98

Mother of Han Chinese ancestry (HG007)

Coriell/NIGMS; PGP

GM24695; RRID: CVCL_1C99

Deposited data

Experimental models: Cell lines

Software and algorithms
Code used to integrate data and form benchmark

This manuscript

Zenodo: https://doi.org/10.5281/zenodo.5907973

BWA MEM

https://github.com/lh3/bwa

GATK

https://gatk.broadinstitute.org/hc/en-us

freebayes

https://github.com/freebayes/freebayes

LongRanger

https://github.com/10XGenomics/longranger

DeepVariant

https://github.com/google/deepvariant

whatshap

https://github.com/whatshap/whatshap/
tree/bb7ccfffc655072451d642b4eea966
1f96b345af

mosdepth

https://github.com/brentp/mosdepth

mrCaNaVar

https://github.com/BilkentCompGen/
mrcanavar

SVRefine

https://github.com/nhansen/SVanalyzer

TrioCanu

https://github.com/marbl/canu

Flye

https://github.com/fenderglass/Flye

bedtools

https://github.com/arq5x/bedtools2

pbsv

https://github.com/PacificBiosciences/pbsv

hap.py

https://github.com/Illumina/hap.py
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REAGENT or RESOURCE

SOURCE

IDENTIFIER

This paper

https://www.nist.gov/programsprojects/genome-bottle

Other
Sequence data, analyses, and resources related
to the NIST Genome in a Bottle Consortium
samples in this manuscript
GIAB stratifications used for benchmarking
v4.2.1 Benchmark VCF and BED files

NIST Public Data Repository: https://doi.org/
10.18434/mds2-2499
This paper

https://ftp-trace.ncbi.nlm.nih.gov/Reference
Samples/giab/release/

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Justin Zook
(justin.zook@nist.gov).
Materials availability
DNA extracted from a single large batch of cells for 5 of the 7 genomes (HG001 to HG005) is publicly available in National Institute of
Standards and Technology Reference Materials 8391 (HG002), 8392 (HG002-HG004), 8393 (HG005), and 8398 (HG001), available
at https://www.nist.gov/srm. DNA for HG001 to HG005, as well as HG006 and HG007, are extracted from publicly available cell lines
GM12878 (HG001, RRID:CVCL_7526), GM24385 (HG002, RRID:CVCL_1C78), GM24149 (HG003, RRID:CVCL_1C54), GM24143
(HG004, RRID:CVCL_1C48), GM24631 (HG005, RRID:CVCL_1C97), GM24694 (HG006, RRID:CVCL_1C98), and GM24695
(HG007, RRID:CVCL_1C99) at the Coriell Institute for Medical Research National Institute for General Medical Sciences cell line
repository.
Data and code availability
d DNA sequencing data were previously deposited in the NCBI SRA under BioProject PRJNA200694 and are publicly available as
of the date of publication. Accession numbers are listed in the key resources table.
d All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOIs are listed in the key
resources table.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon
request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Genome in a Bottle Consortium selected the seven human lymphoblastoid cell lines described in Materials availability for characterization because the pilot female HG001 had extensive pre-existing public data, and HG002 to HG007 are two son-father-mother
trios from the Personal Genome Project that have a broader consent that permits commercial redistribution and recontacting participants for further sample collection.
METHOD DETAILS
Incorporating 10x genomics and PacBio HiFi reads into small variant integration pipeline
v4.2.1 uses the same variant call sets as v3.3.2 from Complete Genomics,28 Illumina PCR-free (novoalign, GATK, and freebayes), and
Illumina mate-pair (bwa mem, GATK, and freebayes).29–31 v4.2.1 uses 10x Genomics linked-read data and the variant calls from the
LongRanger pipeline,6 which makes calls both with and without using information from partitioning reads into haplotypes. In v3.3.2,
we used conservative, haplotype-separated GATK calls from 10x Genomics, where calls were only made separately on each haplotype and coverage from both haplotypes was required. Also, v4.2.1 uses PacBio HiFi data using Sequel II with read lengths of 15 kb
and 20 kb merged into a dataset that has approximately 47x to 68x coverage (Table S1), with variants subsequently called by GATK4
and DeepVariant.7,8 The 10x and PacBio HiFi data provide access to genomic regions that were previously inaccessible to short
reads including segmental duplications. As shown in Table 1 the number of base pairs in the benchmark that covers segmental duplications has increased with the incorporation of long- and linked-read data. Key Resources Table lists the input datasets for the
small variant integration pipeline to produce v4.2.1 for HG002 from 10x Genomics, Complete Genomics, Illumina 150 bp, Illumina
250 bp, Illumina 6 kbp mate-pair, and PacBio Sequel II HiFi/CCS.
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Generating callable files with haplotype-separated BAMs
We use the CallableLoci utility in GATK3 to find regions with good coverage of high mapping quality reads. For PacBio HiFi and 10x
Genomics read data, we use WhatsHap32 haplotag to partition reads by haplotype then use the bamtools filter function to generate
separate BAM files for the two haplotypes. To partition reads by haplotype, we used a vcf that combined 10x linked read phasing with
trio information described in the v0.6 structural variant benchmark paper.3 For CallableLoci with the unseparated BAM, we set the
callable maxDepth threshold to 2 times the median coverage for VCF entries, then the minDepth threshold to 20. For the haplotype
separated BAMs, we use median coverage for VCF as the maxDepth and 5 as the minDepth.
For PacBio HiFi, we first remove multi-allelic entries from the VCF and 50 bp on each side of the variant then remove RefCall entries
with QUAL value below 40 along with 50 bp on each side of those variants. We then find callable regions for each haplotype BAM and
the unseparated BAM then use bedtools multiIntersectBed to find the union of those regions.
For 10x Genomics, we first remove filtered indels along with 50 bp on each side from its callable regions. Then we find callable
regions on each haplotype and the unseparated BAM. After using multiIntersectBed to find the union of those callable regions we
subtract regions that were callable on one haplotype but not callable on the other haplotype.
Python integration
We implemented the integration pipeline using Python as opposed to the Bash and Perl implementation for v3.3.2. The integration
maintains a similar structure and we generated a DNAnexus applet to run on the same platform as v3.3.2. We updated the v4.2.1
pipeline to exclude all of a tandem repeat that is only partially covered by the benchmark regions. We also provide an option to
not provide a callable file for given callsets, which for v4.2.1 we do not use callable regions for Ion Torrent or SOLiD. This results
in a benchmark VCF that includes annotations for those technologies but variants are not excluded based on disagreement with their
calls.
Regions excluded from the benchmark
We determined regions to exclude from the benchmark where it was not currently possible to determine which technologies were
correct due to the difficulty of resolving variation in that region. The difficult regions included those that had a structural variant identified in the GIAB SV v0.6 Benchmark, regions in which the HG002 sample had a copy variation compared to the reference, high depth
and highly similar segmental duplications, tandem repeats >10 kb, regions that are collapsed and expanded from GRCh37/38
Primary Assembly Alignments, modeled centromere and heterochromatin, VDJ, and inversions. The bed files excluded from the
benchmark are being made available in the v3.00 stratifications from GIAB under https://ftp-trace.ncbi.nlm.nih.gov/
ReferenceSamples/giab/release/genome-stratifications/. We refined these regions with several rounds of internal and external
evaluation on intermediate versions of the benchmark. We describe intermediate versions of the benchmark in Table S10.
Modeled centromere and heterochromatin
We use the modeled centromere for GRCh38 from ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/NA12878_HG001/
NISTv3.3.2/GRCh38/supplementaryFiles/genomic_regions_definitions_modeledcentromere.bed and the heterochromatin region ftp://
ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/NA12878_HG001/NISTv3.3.2/GRCh38/supplementaryFiles/genomic_regions_
definitions_heterochrom.bed.33
VDJ region subject to somatic recombination
We downloaded the UCSC genes tracks34 from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/kgXref.txt.gz and
selected entries with ‘‘abParts’’. We then subset to chromosomes 2, 14, and 22 which contain the IGK, IGH, and IGL components
that make up the VDJ recombination regions.
KIR region
v4.2.1 excludes the KIR region (chr19:54716689-54871732 in GRCh38 and 19:55228188-55383188 in GRCh37) because it is highly
variable in copy number in the population, variant representation is challenging, and our current mapping-based methods have more
errors in this region.
Regions that are collapsed and expanded from GRCh37/38 primary assembly alignments
The GRC aligned GRCh37 to GRCh38 (excluding alts) with results available at: ftp://ftp.ncbi.nlm.nih.gov/pub/remap/Homo_sapiens/
2.1/GCF_000001405.13_GRCh37/GCF_000001405.26_GRCh38/. We parsed the file GCF_000001405.13.xlxs for two Discrepancy
values: (1) SP that denotes collapsed regions and (2) SP-only that denotes a region that was expanded between the reference
versions.
Highly similar and high depth segmental duplications longer than 10kb
We begin with the segmental duplications track from UCSC:34 http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/
genomicSuperDups.txt.gz. We filter for entries larger than 10 kb and with identity >99%. We then use bedtools genomecov to calculate segmental depth and subset to those greater than 5.
Potential copy number variation
We employed several approaches to find potential regions of large duplications in HG002 that are not in GRCh37 and GRCh38:
1 Short read and Long Read Intersection: We used mosdepth35 to find 1,000 bp windows that have higher than average coverage/2*2.5
in ONT and PacBio HiFi data. We intersected these regions with results from the CNV analysis tool, mrCaNaVar,36 on Illumina
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HiSeq 300x data (ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/analysis/BilkentUni_IlluminaHiSeq_
TARDIS_mrCaNaVar_05212019/AJtrio-HG002.hs37d5.300x.bam.bilkentuniv.052119.dups.bed.gz and ftp://ftp-trace.ncbi.nlm.nih.
gov/ReferenceSamples/giab/data/AshkenazimTrio/analysis/BilkentUni_mrCaNaVaR_GRCh38_07242019/AJtrio-HG002.hg38.
300x.bam.bilkentuniv.072319.dups.bed.gz).
2 Diploid Assemblies of HG002: We used SVRefine (https://github.com/nhansen/SVanalyzer) to align diploid assemblies to
GRCh37/GRCh38 with bedgraph files that denote coverage of the reference by the number of contigs for the maternal and
paternal haplotypes. We used bedtools unionBedGraphs and then found reference regions that are covered by 2 or more contigs in the union of haplotypes. We did this separately on a TrioCanu assembly using ONT,37 a Flye assembly using ONT,38 and a
TrioCanu assembly of PacBio HiFi 15 kb reads.7 We found an intersection across the three assemblies and subset to regions
greater than 10 kb.
3 Elliptical Outlier Boundary with PacBio HiFi and ONT sequencing data: We used mosdepth to calculate coverage in 1,000 bp windows
of the PacBio HiFi data and the ONT ultralong dataset (ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/
HG002_NA24385_son/Ultralong_OxfordNanopore/guppy-V2.3.4_2019-06-26/ultra-long-ont_hs37d5_phased.bam and ftp://ftptrace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/Ultralong_OxfordNanopore/guppy-V2.
3.4_2019-06-26/ultra-long-ont_GRCh38_reheader.bam). We then found regions that had outlier coverage in PacBio HiFi and/or ONT.
To do so, as described in the equations below, we (1) divided the PacBio HiFi coverage of each window by the median depth HiFi depth
and squared it; (2) divided the ONT coverage of each window by the median depth ONT depth and squared it; (3) summed those values;
and (4) took the square root of the sum. We found the third quartile and interquartile range for those transformed window coverage
values. Finally, we found windows with coverage greater than the third quartile plus 1.5 times the IQR. In the equations below,
WindowHiFiDepth, WindowONTDepth, and EllipticalValues are vectors, while MedianHiFiDepth, MedianONTDepth, and
ThresholdEllipticalOutlier are scalars.

windowHifiDepth = mean HiFi read depth in 1000bp window from mosdepth
windowONTDepth = mean ONT read depth in 1000bp window from mosdepth
MedianHifiDepth = medianðWindowHifiDepthÞ
MedianONTDepthr=ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
medianðWindowONTDepthÞ
. ﬃ

2
2
2
EllipticalValues =
ðWindowHiFiDepth=medianHiFiDepthÞ + ðWindowONTDepth=medianONTDepthÞ
ThresholdEllipcticalOutlier = percentileðEllipticalValues; 75Þ + 1:5  IQRðEllipticalValuesÞ
Inversions
We used SVrefine (github commit f0fb99969b6e239d1f49bc64a8f6cf.5d52a2b88b) to call structural variants with, –maxsize 1000000
option. We then extracted inversions from the call set. Variants were merged with SVmerge (github commit aa8beb6f1cb5c53
9eea9f980ff30d2648caeee21), default maximum "distances", which were 0.2 for all. SVrefine and SVmerge were from SVanalyzer
(https://github.com/nhansen/SVanalyzer).
HG002 v0.6 GIAB Tier1 plus Tier 2 SV Benchmark expanded by 150%
We used bedtools39 slop with parameters -b -pct 0.25 to expand the GIAB v0.6 Structural Variant benchmark file: ftp://ftp-trace.ncbi.
nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/analysis/NIST_SVs_Integration_v0.6/HG002_SVs_Tier1plusTier2_v0.6.
1.bed. This file defines regions in which calls with PASS in the FILTER field as well as regions should contain close to 100% of true
insertions and deletions R50 bp, with variants merged into a single region if they were within 1 kb.
SVs excluded from HG001 and HG003-HG007
Because we don’t have SV benchmarks for HG001 and HG003-HG007, we used pbsv (https://github.com/PacificBiosciences/pbsv)
SVs >49 bp from PacBio HiFi data for HG001 and HG003-HG007, and well as svanalyzer and dipcall SVs >49 bp from trio-hifiasm
assemblies of HG001 and HG005. We expanded these SVs to include overlapping tandem repeats and homopolymers and
expanded the resulting regions by 25% of the region size on each side with bedtools39 slop with parameters -b -pct 0.25.
Tandem repeats greater than 10,000 bp
We took the union of SimpleRepeat dinucleotide, trinucleotide, and tetranucleotide STRs as well as RepeatMasker_LowComplexity,
RepeatMasker_SimpleRepeats, and TRF_SimpleRepeats downloaded from UCSC Genome Browser. We then subset to tandem
repeats longer than 10,000 bp.
Reference assembly contigs shorter than 500,000 bp
We downloaded the gap track from UCSC:34 ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/gap.txt.gz. Then subset to
regions that are gap. We used bedtools complemented with GRCh37/GRCh38 to find contigs then subset to those less than 500 kb.
Regions excluded for specific technologies
We exclude tandem repeats approximately larger than the read length from each method. Tandem repeats shorter than 51 bp
were excluded from all technologies except Illumina PCR-free GATK, Complete Genomics, and PacBio HiFi DeepVariant. We
excluded tandem repeats between 51 bp and 200 bp except for Illumina PCR-Free GATK and PacBio HiFi DeepVariant. Tandem
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repeats between 200 bp and 10,000 bp are excluded from all technologies except PacBio HiFi DeepVariant. Homopolymers greater
than 6 bp were excluded from all technologies except Illumina PCR-free GATK, Complete Genomics, Ion Exome, PacBio HiFi
DeepVariant. Imperfect homopolymers greater than 10 bp were excluded from all technologies except Illumina PCR-Free GATK.
Low mappability regions that are difficult to map for short reads were excluded from all except 10x Genomics and PacBio HiFi.
LINE:L1Hs greater than 500 bp were excluded except Illumina MatePair, 10x Genomics, and PacBio HiFi. Segmental duplications
were excluded from all technologies except 10x Genomics and PacBio HiFi. Homopolymers were excluded from 10x Genomics
and PacBio HiFi. Long homopolymers were included only for GATK based calls for PCR-Free data because GATK gVCF has low
genotype quality score if reads do not totally encompass the homopolymer. Overall we trust homopolymers most from PCR-Free
short reads. We visualize the regions excluded from each sequencing technology in Figure S5.
Comparing v3.3.2 to v4.2.1
For HG002, we subset v3.3.2 variants to v3.3.2 benchmark bed and v4.2.1 variants to v4.2.1 benchmark bed and compared the
benchmarks using hap.py with v2.0 of the GA4GH benchmarking stratifications (https://github.com/ga4gh/benchmarking-tools).5
To identify the types of genomic regions where v4.2.1 gains and loses benchmark variants relative to v3.3.2, we subset to stratifications with at least 1000 variants in v4.2.1, and sorted by the difference between the Precision and Recall metrics, which are measures
of the fraction of extra variants in v3.3.2 and v4.2.1, respectively.
Calculating difficult-to-map, medically-relevant genes coverage
We used the 193 clinically-relevant gene names that contained exons that are difficult to map with short reads from.13 We used
Ensembl BioMart to retrieve Human Genes Build 99 with Gene Name, Start, End, and Chromosome (http://jan2020.archive.
ensembl.org/biomart/martview/2c3a4b803e1a01b3b806829a466b3590).40 We used those results to find coordinates for the difficult-to-map, medically-relevant gene names, subset to genes on chromosomes 1-22, then used bedtools intersect with the
v3.3.2 and v4.2.1 benchmark region files to find overlap.
Evaluation of the benchmark
We used hap.py (https://github.com/Illumina/hap.py) following GA4GH best practices5 with HG002 v4.1 benchmark variants as the
truth set, v4.1 benchmark bed as confident regions, and each of the 12 call sets as the query. We use the vcfeval engine for
comparison.25
To evaluate the utility of the v4.1 benchmark, the GIAB community contributed 13 call sets from short-, linked-, and long-read technologies, and from mapping-, graph-, and assembly-based variant callers. We used hap.py to compare each input callset to v4.1
then asked collaborators to manually curate a small subset of the False Positive and False Negative sites with commands detailed
in ‘‘Supplementary Materials - Benchmark Evaluations’’. Collaborators evaluated 5 False Positive SNVs, 5 False Positive Indels, 5
False Negative SNVs, 5 False Negative Indels both inside and outside v3.3.2 along with 5 False Positive SNVs, 5 False Positive Indels,
5 False Negative SNVs, 5 False Negative Indels in the MHC for GRCh37. We generated IGV sessions with BAM files for Illumina
HiSeq, 10x Genomics, PacBio HiFi 15 kb & 20 kb merged, and ONT Ultralong,11 then asked that the evaluators identify for each
site if both alleles in the benchmark were correct and if both alleles in the query call set were correct.
Variant callsets used in evaluation
PacBio HiFi reads with GATK Haplotype caller
HG002 HiFi reads from three publicly available datasets were aligned to the GRCh37 and GRCh38 references using the pbmm2
v0.10.0 with ‘–preset CCS‘ (https://github.com/PacificBiosciences/pbmm2). The two Sequel I datasets with 10 kb and 15 kb insert sizes
are available at ftp://ftp.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/PacBio_CCS_10kb
and ftp://ftp.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/PacBio_CCS_15kb, respectively
(SRA SRX5327410). The Sequel II dataset with 11 kb insert size is available at ftp://ftp.ncbi.nlm.nih.gov/ReferenceSamples/giab/
data/AshkenazimTrio/HG002_NA24385_son/PacBio_SequelII_CCS_11kb (SRA SRX5527202).
Small variants were called with GATK v4.0.10.1 HaplotypeCaller with ‘–pcr-indel-model AGGRESSIVE‘ and ‘–minimum-mappingquality 10‘ (https://github.com/broadinstitute/gatk/releases/tag/4.0.10.1). Variants were filtered on the QD (Quality by Depth) value
with GATK v4.0.10.1 Variant Filtration, such that:
d
d
d

SNVs with QD < 2 are filtered
Indels > 1 bp with QD < 2 are filtered
1 bp Indels with QD < 5 are filtered

GRCh37 reference used for alignment: ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/reference/phase2_reference_assembly_
sequence/hs37d5.fa.gz
GRCh38 reference used for alignment: ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCA/000/001/405/GCA_000001405.15_GRCh38/
seqs_for_alignment_pipelines.ucsc_ids/GCA_000001405.15_GRCh38_no_alt_analysis_set.fna.gz
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PacBio Hifi reads using minimap2 with DeepVariant
A set of 80x coverage PacBio CCS data was mapped to each reference:
minimap2 VN:2.15-r905
minimap2 -ax asm20 -t 32
(Note that the mapping of these files predates some improved recommendations for mapping to use pbmm2)

DeepVariant v0.8 with the PACBIO model was applied to the mapped files. The commands and workflow used are identical to the
DeepVariant case-study:
https://github.com/google/deepvariant/blob/r0.8/docs/deepvariant-pacbio-model-case-study.md
No filtering is applied.
PacBio HiFi reads realigned using Duplomap
HG002 HiFi reads aligned to the GRCh37 reference using Minimap2 were downloaded from ftp://ftp-trace.ncbi.nlm.nih.gov/
ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/PacBio_CCS_15kb_20kb_chemistry2/ and reads overlapping segmental duplications were realigned using a tool Duplomap (https://gitlab.com/tprodanov/duplomap) that used paralogous
sequence variants to map reads with multiple possible alignment locations. Small variants were called from the realigned bam file
using DeepVariant v.0.8 with default parameters.
10x Genomics using Aquila local assembly
Aquila uses linked-read data for generating a high quality diploid genome assembly, from which it then comprehensively detects and
phases personal genetic variation. Here, Aquila merged two link-reads libraries to generate WGS variant calls for NA24385. Assemblies and VCFs for this merged library L5 + L6 can be found at http://mendel.stanford.edu/supplementarydata/zhou_aquila_2019/
The raw linked-reads fastq files can be downloaded in the Sequence Read Archive and its BioProject accession number is
PRJNA527321.
Illumina TruSeq DNA PCR-Free reads with Illumina Dragen Bio-IT platform
Illumina PCR-Free reads (2 x 250 bp with 350 bp insert size) are downloaded from the public file server.
Dragen 3.3.7 is used to perform alignment, variant calling, and filtering on GRCh37 and GRCh38 reference assemblies. Variant
filtering is based on MQ (Mapping Quality), MQRankSum (Z-score From Wilcoxon rank sum test of Alt vs Ref read MQs), and
ReadPosRankSum (Z-score from Wilcoxon rank sum test of Alt vs Ref read position bias) values. For SNVs, MQ < 30.0,
MQRankSum < 12.5, or ReadPosRankSum < 8.0 are filtered out. For INDEL, ReadPosRankSum < 20.0 are filtered.
Illumina PCR-Free reads are downloaded from
ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/NIST_Illumina_2 3 250bps/
reads/
Illumina TruSeq DNA PCR-Free reads with VG alignment and Illumina Dragen Bio-IT platform
Illumina PCR-Free read pairs (2 x 250bp with 350 bp insert size) are downloaded from and extracted from novoaligned bams that are
hosted on the public file server. The process is based on aligning the HG002 to genome graphs that were constructed from HG003
and HG004 parental variants. All alignments are performed using Variation Graph Toolkit (VG) and variant calling is done using Dragen
version 3.2. Default variant calling settings in Dragen 3.2 were used during GVCF and VCF variant calling. The methods used to
convert graph alignments to linear alignments and parental graph construction are in the workflow defined on the vg_wdl GitHub
repository.
The workflow used to process this data can be found here https://github.com/vgteam/vg_wdl/blob/master/workflows/
vg_trio_multi_map_call.wdl
Illumina PCR-Free reads for the trio used in parental graph construction and HG002 alignment are downloaded from
ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/NIST_Illumina_2 3 250bps/
novoalign_bams/
ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG003_NA24149_father/NIST_Illumina_2 3 250bps/
novoalign_bams/
ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG004_NA24143_mother/NIST_Illumina_2 3 250bps/
novoalign_bams/
The population data used for initial graph alignments of the HG002 trio samples are based on the 1000 genomes phase 3 variant
dataset and the GRCh37 reference genome. http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/ALL.wgs.phase3_
shapeit2_mvncall_integrated_v5b.20130502.sites.vcf.gz
10x genomics using LongRanger with GATK Haplotype Caller
These callsets, generated independently for each individual in the Ashkenazi trio, used LongRanger21 (version 2.2, code at https://
github.com/10XGenomics/longranger) and GATK v4.0.0.0 as variant caller with default parameters on 10x Genomics linked-reads
data for the family trio (84x, 70x, and 69x coverage for HG002 NA24385 son, HG003 NA24149 father, and HG004 NA24143 mother,
respectively) against both GRCh37 and GRCh38. The vcf and bam files for each genome are under:
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ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/analysis/10XGenomics_ChromiumGenome_LongRanger2.
2_Supernova2.0.1_04122018/
The variant curation used the 10x Genomics VCF from LongRanger 2.2 (SRA accession SRX2225480), which is available at: https://
ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/analysis/10XGenomics_ChromiumGenome_LongRanger2.2_
Supernova2.0.1_04122018/GRCh37/NA24385_300G/NA24385.GRCh37.phased_variants.vcf.gz
All samples were sequenced on the Illumina Xten at 2 3 150 bp. The Ashkenazim trio was done using the v1 of the 10x library prep
protocol.
HiFi clair
This callset was generated using Sequel II 11 kbp HiFi reads aligned to the hs37d5 reference with pbmm2, publicly available here:
https://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/data/AshkenazimTrio/HG002_NA24385_son/
PacBio_SequelII_CCS_11kb/. The variants were called by using Clair (v1) on these alignments.
Illumina Novaseq 2 3 250 bp data
The sample HG002 was sequenced on an Illumina Novaseq 6000 instrument with 2 3 250 bp paired end reads at the New York
Genome Center. The libraries were prepped using Truseq DNA PCR-free library preparation kit. The raw reads were aligned to
both GRCh37 and GRCh38 human reference. Alignment to GRCh38 reference, marking duplicates and base quality recalibration
was performed as outlined in the Centers for Common Disease Genomics (CCDG) functional equivalence paper. Alignment to
GRCh37 was performed using BWA-Mem (ver. 0.7.8) and marking duplicates using Picard (ver. 1.83) and local Indel realignment
and base quality recalibration using GATK (ver. 3.4–0). Variant calling was performed using GATK (ver. 3.5) adhering to the best practices recommendations from the GATK team. Variant calling constituted generating gVCF using HaplotypeCaller, genotyping using
the GenotypeGVCFs subcommand and variant filtering performed using VariantRecalibrator and ApplyRecalibration steps. A tranche
cutoff of 99.8 was applied to SNP calls and 99.0 to InDels to determine PASS variants. The raw reads are available for download at
SRA at https://www.ncbi.nlm.nih.gov/sra/SRX7925517, https://www.ncbi.nlm.nih.gov/sra/SRX7925518, and https://www.ncbi.nlm.
nih.gov/sra/SRX7925519.
Long range PCR confirmation
We performed Long range PCR followed by Sanger sequencing for variants in LINEs and difficult-to-map, medically-relevant
genes for all 7 samples. The difficult genes that were chosen for long-range PCR and Sanger sequence confirmation are potentially medically-relevant and have many characteristics that make them difficult to characterize, especially with short reads. We
selected genes with previously published long range PCR assays. The first set of genes make up the RCCX complex, a segmental
duplication that includes TNXA, TNXB, C4A, C4B, and CYP21A2.41,42 The similar sequences of these genes in close proximity
makes them prone to rearrange, mutate and change the size of the complex as a whole, and they are linked to rare diseases
that are inherited together at a higher rate than would be expected by chance. Mutations in the CYP2D6 gene can affect metabolism and bioactivation of many clinical drugs and the gene contains a polymorphic region.43 DMBT1 has been identified as a
candidate tumor suppressor for brain, gastrointestinal and lung cancers and contains highly repetitive sequence.44 Rare variants in
the HSPG2 gene are linked to cases of idiopathic scoliosis.45 STRC has a pseudogene with high genomic and coding sequence
homology making it very difficult to characterize by normal short read sequencing methods.46 The PMS2 gene has multiple pseudogenes, making it difficult to reliably detect mutations or characterize by sequencing.23 We additionally include v4.2.1 variants
covered by the long range PCR assays designed for genes as described for the GIAB Challenging Medically Relevant Gene
benchmark.20
Long range PCR was performed to amplify regions with variants in LINEs and difficult-to-map, medically-relevant genes. Primers
for amplification of LINEs were designed with the Primer3Plus software.47 Other primers were sourced from literature. All long range
primer sequences and references can be found in Table S13. Long range PCR were performed with the PrimerSTAR GXL DNA Polymerase (Takara Bio, Mountain View, CA), and assays specific reaction components can be found in Table S14. Long range PCR
conditions varied by assay and can be found in Table S15.
Sanger primers were designed using the Primer3Plus software.47 Primer sequences can be found in Table S13. Long range PCR
products were purified with ExoSAP-IT (Applied Biosystems, Foster City, CA). Sanger sequencing was performed with SimpleSeq
Premixed Sequencing Kits (Eurofins Genomics, Louisville, KY) using 5 mL of the long range PCR amplicon and 5 mL of 3 mM primer.
Sanger sequencing traces were aligned and analyzed with Geneious Prime (Biomatters, Inc., San Diego, CA).
Phasing variant calls
To provide initial conservative phasing information for regions including the MHC and segmental duplications, the v4.2.1 benchmark vcf for HG002 on GRCh38 was phased in 3 ways. For the MHC, phasing was obtained from the fully phased local
diploid assembly, using trio information to ensure it follows the paternal|maternal convention in the GT field. For the rest of
the genome, we used phased heterozygous calls that were consistent in a single phase block for each chromosome
between trio-based phasing and integrative phasing using Strand-seq and PacBio HiFi reads. The HG002 v4.2.1 benchmark
variants were phased independently from the parental variants using integrative phasing.48 The integrative phasing approach
combined local phase information from PacBio HiFi long-read alignments with global phase information obtained from
Strand-seq short-read alignments to create whole-chromosome haplotypes for each individual. Method and implementation
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were applied as previously described49 with minor modifications: the GRCh38 assembly was used as reference for both
PacBio HiFi long-read and Strand-seq short-read alignments, and the "–indels" option was added to the "whatshap phase"
command line.
Additionally, for the children HG001, HG002, and HG005, we transferred paternal|maternal phasing from a dipcall16 vcf using a
trio-hifiasm v0.11 assembly50 to v4.2.1 vcf of each individual. These draft phased vcfs, which have not been evaluated for accuracy,
are available under the Supplementary Files directory for HG001, HG002, and HG005 at https://ftp-trace.ncbi.nlm.nih.gov/
ReferenceSamples/giab/release/.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical analyses were performed in this work.
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